Annals of internal medicine
-
Comment
Guselkumab safely improved clinical outcomes in biologic-naive patients with psoriatic arthritis.
Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1126-36. 32178766.